Host immune responses to gene therapy: when the immune system meets genetic medicine

In order to exert its therapeutic function, gene therapy needs the host's immune system to tolerate something that it has naturally evolved to notice. Namely, viral particles, synthetic nanoparticles, foreign nucleic acids, newly expressed proteins, or even worse, a creative combination of all the above. Immune recognition is therefore not an unexpected complication of genetic medicine, like some might wrongly believe, but an intrinsic part of its pharmacology. The clinical consequences, however, vary enormously. Innate responses and complement activation can produce acute inflammatory reactions, whereas antibodies and T-cell responses can restrict therapeutic components’ availability, eliminate transduced cells, reduce durability, or make redosing difficult if not impossible. These effects depend not only on the delivery vehicle, but also on cargo, dose, route of administration, target tissue, manufacturing features, and the patient's immunological status and immune history. Here, we provide a concise and critical overview of host responses to viral and non-viral gene therapies, with adeno-associated virus and lipid nanoparticles as the principal clinical examples, and discuss therapeutic proteins and genome editors as additional immunogenic layers. We then focus on what has actually been observed in patients, including transaminitis, complement-associated thrombotic microangiopathy, infusion reactions and selected severe or fatal events. Importantly, gene-therapy toxicity and immunogenicity are not interchangeable concepts. The emerging clinical picture instead supports a more useful view: immune risk is heterogeneous, increasingly mechanistically tractable, and potentially manageable through patient selection, product engineering, dose and route optimization, monitoring and targeted immunomodulation.

Authors

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-13
DOI
https://doi.org/10.3389/fmed.2026.2006852
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Host immune responses to gene therapy: when the immune system meets genetic medicine

Roberto Nitsch
Frontiers in Medicine
Virus-based gene therapy research
article

Host immune responses to gene therapy: when the immune system meets genetic medicine

Roberto Nitsch
article en

Abstract

In order to exert its therapeutic function, gene therapy needs the host's immune system to tolerate something that it has naturally evolved to notice. Namely, viral particles, synthetic nanoparticles, foreign nucleic acids, newly expressed proteins, or even worse, a creative combination of all the above. Immune recognition is therefore not an unexpected complication of genetic medicine, like some might wrongly believe, but an intrinsic part of its pharmacology. The clinical consequences, however, vary enormously. Innate responses and complement activation can produce acute inflammatory reactions, whereas antibodies and T-cell responses can restrict therapeutic components’ availability, eliminate transduced cells, reduce durability, or make redosing difficult if not impossible. These effects depend not only on the delivery vehicle, but also on cargo, dose, route of administration, target tissue, manufacturing features, and the patient's immunological status and immune history. Here, we provide a concise and critical overview of host responses to viral and non-viral gene therapies, with adeno-associated virus and lipid nanoparticles as the principal clinical examples, and discuss therapeutic proteins and genome editors as additional immunogenic layers. We then focus on what has actually been observed in patients, including transaminitis, complement-associated thrombotic microangiopathy, infusion reactions and selected severe or fatal events. Importantly, gene-therapy toxicity and immunogenicity are not interchangeable concepts. The emerging clinical picture instead supports a more useful view: immune risk is heterogeneous, increasingly mechanistically tractable, and potentially manageable through patient selection, product engineering, dose and route optimization, monitoring and targeted immunomodulation.

Frontiers in MedicineVol. 13
Good health and well-being
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon